FDA approves supplemental applications of two hepatitis C drugs for pediatric patients

This article was originally published here

Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for supplemental indications of Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi (sofosbuvir 400 mg) tablets for chronic hepatitis C virus (HCV) infection treatment in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply